ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31

Organogenesis Holdings Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$1.02+0.02 (+2.03%)

Close on Oct 19, 2026

Market cap: $131.25M
P/E (TTM): –
Dividend yield: –

Organogenesis Holdings Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31
Revenue	564	482	433	451	467	338	261	193	199	139
Cost of Revenue	–	116	106	105	114	87	76	69	61	48
Gross Profit	–	366	327	346	353	251	185	125	137	91
Research & Development	45	50	44	40	31	20	15	11	9.07	6.28
Selling, General & Admin	326	295	270	284	250	204	200	162	134	93
Operating Expenses	519	483	421	324	281	224	215	176	143	99
Operating Income	45	-1.28	13	22	72	27	-30	-52	-5.49	-8.78
Interest Expense	-2.28	1.54	2.19	2.01	7.24	11	9.00	11	8.01	5.63
Interest & Investment Income	–	–	–	–	–	–	–	0.06	0.13	0.15
Other Non-Operating Income	2.28	-1.52	-2.13	-2.02	-9.13	-8.94	-8.71	-13	-9.06	-5.93
Merger & Restructuring Charges	0.52	0	3.80	2.27	4.70	0.62	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	–	–	–
Gain (Loss) on Sale of Assets	-0.19	-1.14	-0.24	-4.48	-1.41	-0.20	-0.15	-1.21	0.01	0.01
Legal Settlements	–	–	–	–	–	2.25	–	–	–	–
Pretax Income	47	-2.81	10	20	63	18	-39	-65	-15	-15
Income Tax Expense	9.94	-3.67	5.45	4.75	-31	0.53	0.15	0.08	-7.03	0.07
Net Income incl. Noncontrolling Interests	37	0.86	4.95	16	94	17	-39	-65	-7.53	-15
Minority Interest in Earnings	–	–	–	–	–	–	–	–	0.86	2.22
Net Income	37	0.86	4.95	16	94	17	-39	-65	-8.39	-17
Preferred Dividends	11	1.39	–	–	–	–	–	–	–	–
Net Income to Common	20	-0.94	4.95	16	95	17	-39	-65	-8.81	-0.21
EPS (Basic)(per share)	0.16	-0.01	0.04	0.12	0.73	0.16	-0.42	-0.94	-0.14	-0.27
EPS (Diluted)(per share)	0.15	-0.01	0.04	0.12	0.70	0.15	-0.42	-0.94	-0.14	-0.27
Shares Outstanding (Basic, Weighted)(shares)	127	132	131	130	128	108	93	69	64	63
Shares Outstanding (Diluted, Weighted)(shares)	130	132	133	132	134	111	93	69	64	63
EBITDA	60	12	23	28	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -7.8%
Net margin: -18.4%
Return on equity, FY2025: 13.2%

Financial strength

Current ratio: 3.52
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 80.9%

Valuation

P/E ratio: –
Price to sales: 0.29
Price to book: 0.89
Dividend yield: –